Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP423895.RATe-kcbW2cEN2VpKpVBpzRhEX-wd4Zt-rfV8uhgKAy_s130_assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP423895.RATe-kcbW2cEN2VpKpVBpzRhEX-wd4Zt-rfV8uhgKAy_s130_provenance.
• NP198212.RAnAdJeYBKPRo6lLXAi5r75hTotCv7jqlwEt2A_NPlIs0130_assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP198212.RAnAdJeYBKPRo6lLXAi5r75hTotCv7jqlwEt2A_NPlIs0130_provenance.
• NP417516.RAjqXO0Ux-LAe_5W48mh3uFlxm1TP6ljBHYa_wYW6P-Xs130_assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP417516.RAjqXO0Ux-LAe_5W48mh3uFlxm1TP6ljBHYa_wYW6P-Xs130_provenance.
• NP211684.RANL7A3oz7zcZZDBQdt5-1B80xnn4fn95GOMnumpKGXj0130_assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP211684.RANL7A3oz7zcZZDBQdt5-1B80xnn4fn95GOMnumpKGXj0130_provenance.
• NP468582.RAVdYMrQ4cEp8wSi-hait0ZYCe5hI2zV8rpe9tZHPKgjw130_assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468582.RAVdYMrQ4cEp8wSi-hait0ZYCe5hI2zV8rpe9tZHPKgjw130_provenance.
• NP468907.RARw4_WYS-RGcdP8hA82TZRw1evgl9sdhpKPDmdQguaUs130_assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468907.RARw4_WYS-RGcdP8hA82TZRw1evgl9sdhpKPDmdQguaUs130_provenance.
• NP812414.RAUFt4oOZyFAR8vvUWBfot7McspkNfw4WKkp-72v4a4Rw130_assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP812414.RAUFt4oOZyFAR8vvUWBfot7McspkNfw4WKkp-72v4a4Rw130_provenance.
• assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP738380.RAaoRbrT58cAUvL9y6Y2RaWah7GyJU4c17dp1PqDveGaw130_assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP738380.RAaoRbrT58cAUvL9y6Y2RaWah7GyJU4c17dp1PqDveGaw130_provenance.
• NP738377.RArJpbjzeE0e6em0UWoSgIlseyD077qg7oWSUdaD3yGA4130_assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP738377.RArJpbjzeE0e6em0UWoSgIlseyD077qg7oWSUdaD3yGA4130_provenance.
• NP738375.RALpzDidl8lisaA86QFzjDzQ-PsgiDNastrQTxFePLgYA130_assertion description "[Our findings demonstrate for the first time that Hsp27 knockdown enhances the cytotoxic effects of radiotherapy in vivo and provide preclinical proof of principle for clinical trials using Hsp27 antisense technology in the treatment of patients with HNSCC radioresistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP738375.RALpzDidl8lisaA86QFzjDzQ-PsgiDNastrQTxFePLgYA130_provenance.